I can't answer on the direct injection idea, I'm sure a smart cookie can comment on this. I do know that going for "the covid hype" was an opportunity that allowed a fast track towards this indicator - important for a company with finite time and money. If they just went for all cause ards I doubt we would have been at the point of having commenced a phase 2 trial. I too would love to see them have a 100k patient trial on everything and just go for every indication under the sun all at once, but time and money are factors (as well as patients).
Cell Therapy News/Articles, page-11592
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |